SCHEMBL6787380

SCHEMBL6787380

C/C(=C/C(=O)Nc1ccc(F)cc1C(=O)O)c1cccc(Br)c1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.52
MAPT P10636 2/20 0.52
KMT2A Q03164 2/20 0.52
ABL1 P00519 1/20 0.52
TSHR P16473 1/20 0.52
RIN1 Q13671 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
TERT O14746 5/20 0.52
DHODH Q02127 4/20 0.47
AKR1C2 P52895 3/20 0.46
AKR1C1 Q04828 3/20 0.46
AKR1C4 P17516 1/20 0.46
AKR1C3 P42330 1/20 0.46
TRPM2 O94759 1/20 0.42
GRIK1 P39086 1/20 0.42
DEGS1 O15121 1/20 0.41
POLB P06746 1/20 0.41
GFER P55789 1/20 0.41
KCNK2 O95069 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6790635 0.87 TERT (0.52) TERTDHODHAKR1C2AKR1C1AKR1C4
SCHEMBL4020296 0.82 TERT (0.77) TERTDHODHDEGS1POLBKCNK2
SCHEMBL6785899 0.81 TERT (0.54) MEN1MAPTKMT2ATDP1TERT
SCHEMBL6792289 0.81 TERT (0.48) MAPTTERTDHODHDEGS1
SCHEMBL6785956 0.81 TERT (0.53) TSHRTERTDHODHKCNK2
SCHEMBL6781608 0.79 CYP3A4 (0.53) MEN1MAPTKMT2AABL1RIN1
SCHEMBL6788013 0.79 TERT (0.62) MEN1MAPTKMT2ATDP1TERT
SCHEMBL4024547 0.77 TERT (0.77) MEN1MAPTKMT2ATERTDHODH
SCHEMBL4021470 0.77 TERT (0.77) MEN1MAPTKMT2ATERTDHODH
SCHEMBL6782589 0.77 DHODH (0.58) MEN1MAPTKMT2ATERTDHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 MEN1 896/4885MAPT 1221/4885KMT2A 490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.